Department of Epidemiology, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
mSystems. 2024 Jul 23;9(7):e0053224. doi: 10.1128/msystems.00532-24. Epub 2024 Jun 27.
is the dominant species of the genus in the gut, which is genomically heterogeneous and difficult to isolate; hence, scarce research was carried out for this species. This study aimed to investigate the effect of on hyperglycemia. Thirty-nine strains were isolated from healthy individuals, and three strains (HF2123, HF1478, and HF2130) that had the highest glucose consumption were selected to evaluate the effects of supplementation on hyperglycemia. Microbiomics and non-target metabolomics were used to uncover the underlying mechanisms. Oral administration of in diabetic db/db mice increased the expression and secretion of glucagon-like peptide-1 (GLP-1), significantly improved hyperglycemia, insulin resistance, and lipid accumulation, and alleviated the pathological morphology in the pancreas, liver, and colon. changed the composition of the gut microbiota of diabetic db/db mice, which was characterized by increasing the ratio of Bacteroidetes to Firmicutes and increasing the relative abundance of genera , , and . After intervention with , fecal metabolic profiling showed that fumaric acid and homocysteine contents decreased, and glutamine contents increased. Furthermore, amino acid metabolism and cAMP/PKA signaling pathways were enriched. Our findings indicate that improved glucose metabolism abnormalities in diabetic db/db mice. Especially, one of the strains, HF2130, has shown superior performance in improving hyperglycemia, which may have the potential as a probiotic against hyperglycemia.
As a core member of the human intestinal ecosystem, has been associated with glucose metabolic homeostasis in previous studies. However, these results have often been derived from metagenomic studies, and the experimental studies have been based solely on the type of strain DSM 18205. Therefore, more experimental evidence from additional isolates is needed to validate the results according to their high genomic heterogeneity. In this study, we isolated different branches of strains and demonstrated that could improve the metabolic profile of hyperglycemic mice by modulating microbial activity. This finding supports the causal contribution of in host glucose metabolism.
是肠道中 的优势种，其具有基因组异质性且难以分离；因此，针对该物种的研究很少。本研究旨在研究 对高血糖的影响。从健康个体中分离出 39 株菌株，选择葡萄糖消耗最高的 3 株菌株（HF2123、HF1478 和 HF2130）来评估 补充剂对高血糖的影响。微生物组学和非靶向代谢组学用于揭示潜在机制。在糖尿病 db/db 小鼠中口服 增加胰高血糖素样肽-1 (GLP-1) 的表达和分泌，显著改善高血糖、胰岛素抵抗和脂质积累，并减轻胰腺、肝脏和结肠的病理形态。 改变糖尿病 db/db 小鼠肠道微生物群的组成，其特征是增加拟杆菌门到厚壁菌门的比例，并增加 、 和 等属的相对丰度。用 干预后，粪便代谢组学显示延胡索酸和同型半胱氨酸含量降低，谷氨酰胺含量增加。此外，还富集了氨基酸代谢和 cAMP/PKA 信号通路。我们的研究结果表明， 改善了糖尿病 db/db 小鼠的葡萄糖代谢异常。特别是，其中一株 菌株 HF2130 在改善高血糖方面表现出优异的性能，可能具有作为抗高血糖益生菌的潜力。
作为人类肠道生态系统的核心成员， 先前的研究已将其与葡萄糖代谢稳态联系起来。然而，这些结果通常来自宏基因组研究，而实验研究仅基于菌株 DSM 18205。因此，需要更多来自其他分离株的实验证据来根据其高度的基因组异质性验证结果。在这项研究中，我们分离出不同分支的菌株，并证明 通过调节微生物活性， 可以改善高血糖小鼠的代谢谱。这一发现支持 对宿主葡萄糖代谢的因果贡献。
